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OBJECTIVE — To evaluate facility rankings in achieving 7% A1C levels based on the
complexity of glycemic treatment regimens using threshold and continuous measures.
RESEARCH DESIGN AND METHODS — We conducted a retrospective administra-
tive data analysis of Veterans Health Administration Medical Centers in 2003–2004. Eligible
patients were identiﬁed using National Committee for Quality Assurance (NCQA) measure
speciﬁcations.Acomplexglycemicregimen(CGR)wasdeﬁnedasreceiptofinsulinorthreeoral
agents.Facilitieswererankedusingﬁveordinalcategoriesbasedupbothzscoredistributionand
statistical signiﬁcance (P  0.05). Rankings using the NCQA deﬁnition were compared with a
subset receiving CGRs using both a 7% threshold and a continuous measure awarding pro-
portional credit for values between 7.9 and 7.0%. Ranking correlation was assessed using the
Spearman correlation coefﬁcient.
RESULTS — A total of 203,302 patients (mean age 55.2 years) were identiﬁed from 127
facilities(range480–5,411,mean1,601);26.7%(17.9–35.2%)werereceivingCGRs,including
22.0%receivinginsulin.MeanA1CandpercentachievingA1C7%were7.48and48%overall
and8.32and24.8%forthosereceivingCGRsusingthethresholdmeasure;proportionachieved
was 60.1 and 37.2%, respectively, using the continuous measure. Rank correlation between the
overall and CGR subset was 0.61; 8 of 24 of the highest or lowest ranked facilities changed to
nonsigniﬁcance status; an additional ﬁve sites changed rankings.
CONCLUSIONS — Facility rankings in achieving the NCQA 7% measure as speciﬁed
differ markedly from rankings using the CGR subset. Measurement for public reporting or
payment should stratify rankings by CGR. A continuous measure may better align incentives
with treatment intensity.
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T
he National Committee for Quality
Assurance (NCQA)-Healthcare Em-
ployer Information Data Set (HEDIS)
measure for good (7% A1C) glycemic
control was revised in 2009 to apply only
to individuals 65 years without cardio-
vascular diseases, end-stage diabetes
complications, or dementia (1). Although
most patients will require the use of insu-
lintoachievetightcontrolwithin10years
of diagnosis (2), even short-term attain-
ment of an A1C level 7% may be difﬁ-
cult for such individuals (3,4). In a
representative sample of the U.S. popula-
tion, receipt of insulin resulted in a 14%
decrease in the number of individuals at-
taining a 7% threshold (5). Because the
frequency and risk of hypoglycemia may
be a concern (6), multiple guidelines rec-
ommend that glycemic control targets
shouldbeindividualizedforsuchindivid-
uals, especially in the presence of comor-
bid medical and mental health conditions
(7). Furthermore, individuals with diabe-
tes may choose not to initiate insulin for
suboptimal glycemic control even when
recommended (8). Thus, any perfor-
mance measure, especially one used for
public reporting or provider payment,
should take into account case mix differ-
encesamongpopulations.Althoughthere
are no validated risk adjustment models
for glycemic control, one potential indi-
catorofcasemixisthetypeandcomplex-
ity of the medication regimen used (5).
The Veterans Health Administration
(VHA) is the nation’s largest integrated
health care system and has national data
repositories of individual administrative,
pharmacy, and laboratory records (9).
Our study objective was to compare
changesinfacility-levelrankingsbasedon
the NCQA-HEDIS measure, as currently
speciﬁed,withrankingsbasedonasubset
of patients receiving either insulin or
three oral agents. We hypothesized that
the identiﬁcation of “best” and “worse”
performing facilities would differ be-
tweenthesegroups.Additionalobjectives
were to compare rankings using the
threshold measure with those using a
continuous measure that awarded incre-
mental credit for improvement between
7.9% and 7.0% A1C (10), and to eval-
uate the impact of excluding additional
serious medical and mental illnesses.
RESEARCH DESIGN AND
METHODS
Data sources and patient
identiﬁcation
Inpatient and outpatient utilization data,
ICD-9-CM codes, and diagnostic codes
were obtained from the National Patient
Clinical Dataset (Austin, TX), laboratory
datawasobtainedfromtheDecisionSup-
port System, and medication data were
from the Pharmacy Beneﬁts Management
Program(11).ToapproximateNCQAcri-
teria for continuous enrollment, patients
were eligible if they received care within
the VHA in ﬁscal year 2003 (1 October
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VHA care in FY2004, and had a diagnosis
of diabetes. The latter was deﬁned as two
or more diabetes ICD-9 codes (250,
357.2, 362.0, and 366.41) associated
with clinical outpatient care on separate
calendar days or any diabetes-speciﬁc
medication prescription (insulin, sulfo-
nylureas, biguanides, -glucosidase inhibi-
tors, meglitinides, and thiazolidinediones).
Individuals for whom death was ascer-
tained before 30 September 2004 were
excluded. We eliminated veterans with-
outanA1CtestinVHAdatabasesbecause
results done outside the VHA cannot be
differentiated from nonperformance of
the test.
Patients were deﬁned as having a
complex glycemic regimen (CGR) if they
were receiving either insulin or three oral
agents. Such patients would be consid-
ered to have received maximal oral agent
therapy, especially if they were receiving
thiazolidinediones. During this period,
the VHA Pharmacy Beneﬁts Management
(12) classiﬁed thiazolidinediones as
third-line therapy and facilities moni-
tored their usage.
Denominator exclusion criteria
Thedenominatorfortheprimaryanalyses
was based on current NCQA-HEDIS
criteria that exclude individuals with car-
diovascular conditions, end-stage com-
plications of diabetes (blindness,
amputations, and end-stage renal dis-
ease), and dementia based on one
ICD9-CM or Current Procedural Termi-
nology (CPT) code in either the calendar
yearorprecedingyear(1).Toevaluatethe
impact of other chronic illnesses on facil-
ity rankings, we similarly identiﬁed and
excluded patients in the NCQA denomi-
nator for conditions in the following cat-
egories, as previously described (13):
decreased life expectancy (cancers [ex-
cept basal and squamous skin cancers]
and end-stage hepatic disease); advanced
(but not end-stage) complications of dia-
betes (advanced retinopathy [prolifera-
tive disease, prior laser treatment, retinal
detachment, macular edema, and vitre-
ous hemorrhage] without blindness);
chronic renal disease; gastroparesis; po-
tentially disabling neurological diseases
(Parkinson’s disease and spinal cord in-
jury); major mental health conditions
(majordepression,schizophrenia,andbi-
polar disorder); and substance abuse. Pa-
tients with these conditions were
considered to have decreased beneﬁt
and/orincreasedriskfromintensivetreat-
ment (7).
Analysis
We evaluated the distributions of glyce-
mic control for all patients in the NCQA
denominator, as well as for patients strat-
iﬁed by CGR and non-CGR status (using
both 0.1% A1C increments and ordinal
intervals). At the facility level, we deter-
mined the proportion of patients who
achieved 7% A1C based upon the last
A1C test in FY04 within the speciﬁed de-
nominators. To increase the reliability of
facility rankings, we speciﬁed that a facil-
ity must have at least 100 patients receiv-
ing CGRs (14).
In addition to the use of the NCQA
measure, we also evaluated the use of a
continuous measure that would provide
partial credit for A1C values between 7.9
and 7.0% and full (100%) credit for val-
ues 7.0% (10). In contrast, a threshold
measure (such as 7% A1C) awards
100% credit only for values 7% and no
credit for any values 7%. In brief, be-
cause the lifetime absolute risk reduction
of microvascular complications resulting
fromlowerA1Cislinearwithinthisrange
(as opposed to a log-linear absolute risk
reduction when starting at higher A1C
levels), arithmetic interpolation was used
to equally weight each 0.1% decrease in
A1C.
Facility rankings were determined by
assigning facilities into ﬁve ordinal cate-
gories based on both z score distribution
(10% [ﬁve stars or best], 10–33% [four
stars], 34–66% [three stars], 67–90%
[two stars], and 90% [one star or
worst]) and statistical signiﬁcance (P 
0.05)(15).Statisticalsigniﬁcancewascal-
culated using the interval as follows:
(Facility rate  Overall mean rate)
 1.96SE facility
2
 SE overall
2
Signiﬁcance was assumed if the interval
did not include zero. Differences in rank-
ing were assessed using the Spearman
correlation coefﬁcient and movement of
facilities between the categories. The
study was approved by the institutional
review boards of the East Orange and
Cleveland VA Medical Centers.
RESULTS— We identiﬁed 378,112
patients with diabetes who were 65
years of age at the onset of FY2004 (sup-
plementary Fig. 1, available in an online
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-1665). We ex-
cluded 63,753 patients because A1C
results were not available in VHA data-
bases. An additional 108,901 patients
were excluded based on the NCQA tech-
nical measure speciﬁcations. Finally,
2,156 patients were excluded from six
sites with 100 patients receiving CGRs.
The ﬁnal study sample was 203,302 pa-
tients from 127 facilities, 54,351 (26.7%)
of whom received a CGR, including
22.0% receiving insulin (Table 1). Of pa-
tients receiving three oral agents, 93.7%
were taking a thiazolidinedione. The fa-
cility range for CGRs was 17.9–35.2%
(notshown).Themeanageofthepatients
was 55.2 years, with 16.6% aged 50
years. The mean A1C was 7.48% for all
patients,8.32%forthosereceivingCGRs,
and 7.17% for those not receiving CGRs.
The NCQA denominator included an ad-
ditional 74,531 (36.7%) individuals with
at least one serious medical or mental
health condition, including psychoses or
substanceabuse(23.5%),conditionswith
limited life expectancy (6.2%), advanced
renal or retinal complications of diabetes
(4.5%), serious neurological conditions
(4.2%), and serious medical conditions
(6.9%).
The A1C distributions were similar
for the NCQA and non-CGR denomina-
tors but differed markedly for the CGR
denominator (Fig. 1). Of the patients not
receiving CGRs, 56.0% had A1C values
7%, 12.6% had A1C values of 7.0–
7.4%, and 8.8% had AIC values of 7.5–
7.9%, compared with 24.8, 12.2, and
12.2% for the patients receiving CGRs.
Compared with the non-CGR denomina-
tor, in which 22.6% had A1C values
7.9%, there was increased skewness of
the NCQA and CGR denominators, for
which the proportions were 30.1 and
50.7%, respectively.
At the facility level, the mean and
range of percent achievement of a 7%
threshold varied considerably between
the NCQA and CGR denominators for
each ranking category (Table 2). For ex-
ample, the top 10% performing facilities
overall achieved a rate of 57% (range 54–
62%) compared with 34% (31–38%) for
individuals receiving CGRs. The use of a
continuous measure increased the per-
cent achievement compared with the di-
chotomous measure by 12% for both the
overall and CGR denominator. There was
anoverall1.2%lowerachievementforthe
denominator that used additional exclu-
sion criteria (data not shown).
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rankings using the NCQA measure with
the CGR denominator was 0.61 and in a
sensitivity analysis was 0.65 for A1C
7.5% and 0.74 for A1C 8%. The cor-
relation was 0.97 with the additional ex-
clusion criteria denominator. Rankings of
both the aggregate and CGR denomina-
tors using the dichotomous threshold
were comparable to those using a contin-
uous measure (0.96 and 0.90).
However, the identiﬁcation of best
and worst facilities differed markedly be-
tween the NCQA denominator (all pa-
tients) and the CGR denominator (Table
3). In this comparison, 8 of 24 facilities
that were statistically different identiﬁed
as being best (ﬁve stars) or worst (one
star) using the NCQA measure became
not signiﬁcantly different (three stars),
and an additional 5 of 24 moved up in
ranking. Overall, 42 of 68 (62%) facilities
ranked statistically better or worse using
the NCQA denominator were ranked as
average (not statistically different) using
the CGR denominator; 12 of 59 (20%)
ranked average became signiﬁcantly
higher or lower. Six of the 31 four- or
ﬁve-star ranked facilities were ranked
lower when exclusion criteria for signiﬁ-
cant comorbid conditions were applied.
CONCLUSIONS — We demonstrated
that overall rankings of VHA facilities
based on achievement of the NCQA-
HEDIS 7% A1C measure as speciﬁed
were only modestly correlated with rank-
ings for the subset of patients receiving
CGRs. When evaluated based on the
NCQA-HEDIS practice of awarding
“stars” to denote plan quality rankings,
approximately two-thirds of facilities
rankedbest(fourorﬁvestars)overalland
about 6 of 10 of those ranked worst (one
or two stars) on the current measure were
ranked average (three stars, not statisti-
cally different) when evaluated using the
CGR denominator.
Although it is possible that the ob-
served difference in rankings between the
NCQA measure and the CGR denomina-
tor may reﬂect differences in quality of
care provided to patients receiving more
complextreatmentregimens,itcouldalso
reﬂect patient characteristics among facil-
ities. For example, in the current study,
the facility percentage of patients receiv-
ingCGRsvariedtwofold(17.9to35.2%).
In a prior study (16), the 10th and 90th
percentile of VA facilities differed mark-
Table 1—Characteristics of NCQA denominator, CGR denominator, and NCQA denominator with additional exclusion criteria
Attribute (FY 2004)
NCQA
denominator
Non-CGR
denominator
CGR
denominator
NCQA denominator,
additional exclusions
Total N 203,302 148,951 54,351 128,771
Mean n per facility (SD) 1,601  933 1,173  688 428  252 1,014  599
Range 480–5,411 347–4,176 109–1,490 276–3,553
Age (years) 55.2  6.3 55.5  6.1 54.4  6.8 55.4  6.4
50 years (%) 16.6 15.4 20.1 15.8
50–64 years (%) 83.4 84.6 79.9 84.2
Sex (%)
Female 4.9 4.9 4.6 4.6
Male 95.2 95.1 95.4 95.4
Veterans’ priority (%)
Missing 1.2 1.3 0.8 1.4
50% SC disability 25.0 22.7 31.2 19.5
30–40% SC disability 10.0 9.9 10.1 11.1
Other disability, POW, etc. 14.2 14.8 12.6 16.3
Catastrophic disability 2.9 2.4 4.1 1.1
Poverty 30.1 30.7 28.7 29.9
Other 1.5 1.7 0.7 1.8
Copay 15.2 16.4 11.8 18.9
Marital status (%)
Married 55.5 56.3 53.4 60.4
Other 44.5 43.8 46.6 39.6
Medication proﬁle (%)
No medications 32.4 44.2 NA 35.6
OHA only 45.7 55.9 17.8 46.2
3 OHAs 4.8 NA 17.8 5.2
1 or 2 OHAs 40.9 55.9 NA 41.0
OHA and insulin 13.9 NA 52.0 11.9
Insulin only 8.1 NA 30.2 6.3
A1C level (%) 7.48  1.83 7.17  1.66 8.32  1.99 7.50  1.77
Decreased life expectancy (%) 6.2 6.1 6.7 NA
Advanced complications (%) 5.0 3.3 9.5 NA
Serious medical conditions (%) 6.9 5.5 10.7 NA
Serious neurological conditions (%) 3.7 3.4 4.6 NA
Serious mental health conditions (%) 23.5 22.3 26.9 NA
Data are means  SD or %. OHA, oral hypoglycemic agent; POW, prisoner of war; SC, service connection; NA, not available.
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duration of diabetes 11 years (30.1 and
41.8%), no high school diploma (18.9
and 44.2%), concern over food sufﬁ-
ciency (9.3 and 19.5%), and BMI 35
(11.2 and 19.9%) (16). Facilities with a
greater proportion of patients with com-
plex treatment regimens may be at a dis-
tinct disadvantage in achieving a 7%
threshold.
Our results are relevant to organiza-
tions that develop and endorse diabetes
measures as well as stakeholders who rely
upon them for inferences regarding qual-
ity of care. Individuals in whom therapy
with two oral agents has failed may be
reluctant to start insulin therapy because
of valid concerns regarding the beneﬁts,
risks, costs, and time requirements of in-
sulin treatment (8). However, thiazo-
lidinediones have demonstrated only
limited efﬁcacy as third-line agents in
achieving and maintaining A1C 7%
(17),andthelong-termefﬁcacyandsafety
of newer classes of antiglycemic medica-
tions as third-line therapy are not yet
known.
Furthermore, only about one-third of
highly selected patients started on basal
insulin(4,18)andabouthalfusingacom-
bination of long-acting insulin and pran-
dial insulin (3) can achieve and maintain
A1C 7% over 26–52 weeks. Frequent
or severe hypoglycemia may be neither
acceptable nor safe for many patients, es-
pecially those with comorbid conditions
and less willingness or ability to comply
with recommended self-management.
Therefore, the feasibility of achieving
7% A1C in individuals with diabetes of
longer duration in general clinical prac-
tice is not known.
Consequently, reliance on a 7%
threshold measure as the “quality stan-
dard” for public reporting or pay for per-
formance could have the unintended
consequence of adversely affecting pa-
tient safety. Recent trials have demon-
strated the potential risks of serious
hypoglycemia even in patients who can-
not achieve a 7% target (6), and there
are signiﬁcant costs associated with insu-
lin-related hypoglycemia even among
employedindividuals(19).Moreover,the
truevalueofasingleA1Ctestresultof7%
from an accredited laboratory can be
within a 6.65 to 7.35% range, assuming a
permissible intra-assay coefﬁcient of vari-
ation of 5% (20). Point-of-care assays are
even more variable, yet A1C testing in the
physician ofﬁce is exempt from external
oversight (20). Clinical decisions to initi-
ateorintensifyinsulinneedtobemadeon
Figure1—ThepercentagesofA1Cvaluesoccurringin0.1%intervalsareplottedseparatelyforeachofthedenominators.Thepercentagewithineach
nonoverlapping A1C range within each denominator is reported. Relatively similar distributions are observed for the NCQA (‚) and non-CGR(F),
whereastheCGR(f)distributiondifferedmoremarkedlyinbothskewnessandkurtosisasaresultofagreaterproportionofpatientshavinghigher
A1C values.
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ual patient trends in A1C and self-
monitoring results rather than a single
A1C value that is marginally higher (i.e.,
within laboratory error) than the perfor-
mance measure (21). We propose that
ratherthanassessing“goodglycemiccon-
trol” by an all-or-none threshold, devel-
opers should provide credit for an A1C
result within an acceptable range to bal-
ance the tradeoffs of beneﬁts, harms, and
patient preferences.
Alternatively, a continuous measure
that can assess incremental improvement
toward an A1C 7% target for patients
receiving CGRs may have signiﬁcant de-
sirable attributes over an all-or-none
threshold measure with respect to rele-
vance, scientiﬁc soundness, and feasibil-
ity. At the population level, it would
provide more information for inferential
hypothesis testing compared with a cate-
gorical or binomial measure (22) and
could minimize statistical variation at a
population level due to either A1C mea-
surement accuracy and bias (20) or sea-
sonal variation (23). It is also consistent
with the evolving quality improvement
literature that demonstrates the difﬁculty
inincreasingattainmentof7%A1C,es-
pecially in patients with starting A1C lev-
els8%,despitestructuredinterventions
in staff model practice settings with elec-
tronic health care records (24). Because it
is not possible to identify type 1 diabetes
or duration of disease using administra-
tive data, stratiﬁcation by treatment regi-
men is a pragmatic approach that can
minimize attribution error; that is, better
glycemic control is incorrectly inter-
preted as improved plan quality when
it actually reﬂects a greater proportion
of patients with recent-onset diabetes
(patients not receiving CGRs) in the
denominator.
In addition, from both an individual
and a population health perspective,
thereisagreaterhealthbeneﬁtfromtreat-
ing higher A1C values (8%) than values
marginally 7%. A continuous measure
can better reward the additional time and
costs of a multidisciplinary team ap-
proach spent on intensive therapy of pa-
tients with complex treatment regimens
even if they do not reach the 7% “goal.”
This strategy could incentivize physician
practices to compete for referrals or enter
into contractual relationships with endo-
crinologists or disease management pro-
grams, thus focusing scarce resources on
the most difﬁcult patients with the great-
est need.
Finally, although exclusion criteria
had a minimal impact on rankings, we
suggest that performance measure devel-
opers incorporate additional exclusion
criteria that would be consistent with
guideline recommendations (7). Because
the current measure excludes individuals
with a single cardiovascular ICD9-CM
code regardless of therapy, it seems rea-
sonable to either exclude or stratify pa-
tients with comorbid conditions that
might increase the risk of serious hypo-
glycemia with CGRs. Further study is
needed to deﬁne the sensitivity and spec-
iﬁcity of algorithms to identify such
patients.
Our study is limited by the ability to
assess severity of chronic disease or pa-
tient level factors using administrative
data. We also did not determine the start-
ing point for glycemic control, medica-
tion persistence, or adverse events
(including hypoglycemia). However,
these are general limitations of using only
administrative data for evaluation of in-
dustrystandardcross-sectionalmeasures.
Additional studies are necessary to ascer-
tain whether our ﬁndings in the VHA are
generalizabletootherhealthcaresystems.
In summary, the assessment of the
quality of good glycemic control among
Table 2—Achievement of A1C threshold and continuous measure within ordinal ranks using NCQA, additional comorbid condition exclusions
and CGR denominators
NCQA star ranking
5 stars 4 stars 3 stars 2 stars 1 stars Total
NCQA denominator measured using 7% threshold: No. facilities 12 19 59 25 12 127
Proportion 7% minimum (%) 54 51 45 41 34 34
Proportion 7% maximum (%) 62 54 52 46 41 62
Mean proportion 7% (%) 57 53 48 44 39 48
NCQA denominator with additional exclusions removed 12 17 67 19 12 127
Proportion 7% minimum (%) 53 50 43 40 33 33
Proportion 7% maximum (%) 62 53 51 45 40 62
Mean proportion 7% (%) 57 51 47 42 37 47
NCQA denominator measured using continuous measure 12 21 57 25 12 127
Proportion achieved: minimum (%) 66 62 57 54 46 46
Proportion achieved: maximum (%) 75 66 64 58 54 75
Mean proportion (%) 69 64 60 56 52 60
CGT denominator measured using 7% threshold 12 4 89 10 12 127
Proportion 7% minimum (%) 31 29 19 19 13 13
Proportion 7% maximum (%) 38 30 30 21 18 38
Mean proportion 7% (%) 34 30 25 20 17 25
CGR denominator measured using continuous measure 12 8 85 10 12 127
Proportion achieved: minimum (%) 44 41 31 31 28 28
Proportion achieved: maximum (%) 51 44 41 33 30 51
Mean proportion (%) 47 42 37 32 30 37
Data are n or %. Within each denominator, facilities were ranked within ﬁve ordinal categories based on both z score distribution (10% 5 stars or best; 10–33%
4 stars; 34–66% 3 stars; 67–90% 2 Stars, and 90% 1 star or worst) and statistical signiﬁcance (P  0.05). The minimum, maximum, and mean proportion
of patients meeting the measure are presented for the facilities included within each category.
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HEDIS measure compared with a subset
of patients receiving complex glycemic
treatment regimens. Our recommenda-
tion to stratify measures by CGR and to
award partial credit using a continuous
measures are consistent with proposals
madeata2006AHRQfundedconference
(25). Although the use of a single number
for all enrollees to reﬂect the quality of
glycemic treatment within a plan may be
attractive in its simplicity, it is superﬁcial
and may be misleading. A lack of an ap-
preciation of the hidden complexities of
care and measurement by policy makers
and managers may thus result in actions
that have unintended and potentially
harmful consequences for patients, pro-
viders, plans, and society.
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